Progesterone in Medical Technology

Reproductive Partners Participates in New IVF Progesterone Delivery System Study

... in a national study to explore new IVF progesterone delivery systems replacing intramuscular ... in a national, multi-center study exploring new progesterone delivery systems to replace intramuscular ... in vitro fertilization (IVF) often describe the progesterone injections as the most difficult and painful part ...

Nationwide Survey Shows Infertility Patients Prefer ENDOMETRIN(R) Compared With Other Progesterone Supplements

... and pain-free administration. Adequate progesterone support is considered extremely important for a successful pregnancy. Since natural progesterone production may be compromised by ART, progesterone supplements are used extensively for luteal phase ...

Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit

... at risk for preterm delivery who can benefit from progesterone treatment, the March of Dimes Foundation said ... no prior history of preterm birth) who received progesterone suppository treatment between 24 and 34 ... those women who are most likely to benefit from progesterone treatment from those who are not." Dr. Katz ...

Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World

... New, Patient-Friendly progesterone Supplement ATLANTA, Aug. 2 /PRNewswire/ -- ... (progesterone) Vaginal Insert, 100 mg, a progesterone supplement used in patients undergoing assisted ... As the first new, patient-friendly alternative to progesterone supplementation in a decade, ENDOMETRIN was shown ...

Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival

... with metastatic TNBC, defined as tumors lacking expression of estrogen and progesterone receptors and without overexpression of HER2, were randomly assigned to ... cancer, their tumors are routinely tested for the presence of estrogen and progesterone receptors and for the over-expression of HER2. Commonly used breast cancer ...

Methadone Frequently Causes Menopausal Symptoms in Young Women

... May 7 /PRNewswire/ -- Methadone medication frequently depresses estradiol, progesterone and testosterone hormone levels to menopausal levels, even in women less ... 20 and 30 years old, who we detoxed from methadone arrived with estradiol, progesterone or testosterone hormone levels, in the post menopausal range." A ...

Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF

... 5 /PRNewswire/ -- Women undergoing in vitro fertilization (IVF) require progesterone medication to help support early pregnancy, but the intramuscular ... forms of this medication can be painful for patients. Formulations of progesterone medication which can be administered by subcutaneous injection or vaginal ...

Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)

... decisions." Reporting of Quantitative Estrogen Receptor and progesterone Expression with Oncotype DX * A study presented by Kaiser Permanente ... other results, Genomic Health plans to provide individual estrogen and progesterone receptor scores as an enhancement to Oncotype DX Recurrence Score ...

UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201

... III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or without BSI-201, in patients with Estrogen Receptor (ER), progesterone Receptor (PR), and HER2-negative metastatic breast cancer. Joyce O'Shaughnessy, M.D. , co-chair of the US Oncology Breast Cancer Research ...

Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference

... work together to inhibit the growth of triple-negative breast cancer cells. "Triple-negative" refers to breast cancer cells that have no estrogen, progesterone or HER2 receptors needed for currently-available, targeted anticancer therapies to work effectively. AFP464 is now in Phase I clinical trials at ...

EntreMed Presents Initial Clinical Results for ENMD-2076

... human breast carcinoma model. Triple-negative breast cancer is a specific subtype of breast cancer that does not express estrogen receptor, progesterone receptor, or Her2 genes. This subtype is more aggressive and less responsive to standard treatment and is also associated with poorer patient ...

Agendia Launches TargetPrint(R) for Breast Cancer Patients

... of TargetPrint(R), a new diagnostic test that allows physicians to quantitatively determine the gene expression levels of the estrogen receptor (ER), progesterone receptor (PR) and Human Epidermal growth factor Receptor 2 (HER2) in breast cancer tumor biopsies. The accurate measurement of these receptors is of ...

Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies

... in intergroup trial E2197," (abstract 557) was led by the Eastern Cooperative Oncology Group (ECOG). Researchers evaluated the predictive utility of progesterone receptor (PR) protein expression by IHC in a central lab and quantitative RNA expression by RT-PCR for 371 genes, including the current Oncotype DX ...

Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy

... following St Gallen 1998 criteria: patient's age <35 years, tumor histological grade II/III, tumor size >2 cm, or hormone-receptor (estrogen and/or progesterone receptor) negative tumor. The 1059 women enrolled in this multicenter, phase III study were randomized to receive either TAC (n=539) or FAC (n=520) ...

AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients

... by measuring the functionality of the estrogen signaling pathway inside the tumor cell itself. As such, H/I goes beyond conventional estrogen and progesterone receptor (ER/PR) testing. While patients who are ER/PR positive are assumed to benefit from endocrine therapy, the therapy fails in approximately 25 ...

BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data

... has initiated a Phase 2 study of its lead PARP inhibitor, BSI-201, in patients with triple-negative breast cancer that do not express the estrogen, progesterone or HER2 receptors. The company designed the Phase 2 trial in this indication-which represents a major unmet medical need-based on molecular ...

Ferring Reports on ENDOMETRIN Presentations at Pacific Coast Reproductive Society Annual Meeting

... progesterone Vaginal Supplement Studied in Largest-Ever IVF ... Ferring Pharmaceuticals' ENDOMETRIN(R), a novel progesterone vaginal insert in development for luteal ... April 18 to 22, 2007. ENDOMETRIN is micronized progesterone in a tablet form that is vaginally inserted with ...

Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal

... pregnancies in 400 women treated with CRINONE 8% progesterone vaginal gel versus compounded progesterone intramuscular injections. The study is being ... 8%. "The fact that CRINONE 8% delivers the progesterone needed to achieve and maintain pregnancy has been ...

Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth

... PROCHIEVE 8%, and suggest a correlation between the cervical length data, progesterone administration, and both a reduction in the likelihood of preterm birth ... of Assisted Reproductive Technology treatment for infertile women with progesterone deficiency, and PROCHIEVE 4% (progesterone gel) for the treatment of ...

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

... are induced via a known carcinogenic compound. In the study, the hormone progesterone was shown to increase the number of growing tumors. Conversely, ... in 2005. Women whose primary lesions contain both estrogen and progesterone receptors are typically treated with anti-estrogens or aromatase ...

Repros' Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids

... address conditions of the male and female reproductive systems. Proellex(TM), the Company's lead compound, is a selective blocker of the progesterone receptor. Having successfully completed the above Phase 2 trial the Company believes Proellex will enter Phase 3 studies later this year for the ...

Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women

... of early recurrence had tumours larger than five centimetres, four or more positive nodes, positive oestrogen receptor status but negative progesterone status, grade three tumours and invasive disease. Notably, women with node positive disease, who are considered to be at a higher risk of recurrence, ...

Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine

... drug delivery technology. Columbia markets CRINONE(R) 8% (progesterone gel) and PROCHIEVE(R) 8% (progesterone gel) in the United States for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile women with progesterone deficiency and PROCHIEVE 4% ...